SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?


To: smh who wrote (27749)1/31/1999 10:42:00 PM
From: Henry Niman  Respond to of 32384
 
Target potential for Targretin is huge since animal data has demonstrated applications for type Ii diabetes as well as several cancers, including breast cancer. Prior estimates have put LGND's rexinoid/retinoid annual sales north of $500 million.